ArticlePediatric research2026
Serum FAM132A/Adipolin correlates with endothelial dysfunction in children with obesity.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly cardiovascular risk in children demands biomarkers linking adiposity to vascular injury. We examined whether serum FAM132A (Adipolin) associates with endothelial dysfunction markers in Chinese children with obesity.
methodsIn a STROBE-guided single-center case-control study (Sep 2023-Mar 2024), we enrolled 82 children with obesity and 50 age-matched normal-weight controls; all participants underwent clinical assessment and anthropometry, and serum FAM132A, adiponectin, leptin and endothelial markers VCAM-1, E-selectin and ESM-1 were measured by ELISA. Multiple linear regression tested independent associations with adjustment for age, sex, pubertal stage, HOMA-IR and leptin.
resultsMean FAM132A was higher in the obesity group (0.97 ± 0.13 vs 0.79 ± 0.07 ng/ml, p < 0.001) and correlated positively with BMI, SDS-BMI, WHR, ALT and the three endothelial markers. In fully adjusted models FAM132A independently predicted VCAM-1 (β = 1.110, p = 0.040), E-selectin (β = 1.210, p = 0.043) and ESM-1 (β = 1.257, p = 0.041); these associations persisted after accounting for insulin resistance and were independent of classic adipokines.
conclusionSerum FAM132A is paradoxically elevated in pediatric obesity and independently associated with endothelial activation, suggesting compensatory upregulation in early metabolic stress and potential utility as an early vascular injury biomarker and merits longitudinal validation. IMPACT: Serum FAM132A elevated in obese Chinese children. FAM132A correlates with endothelial markers VCAM-1, E-selectin, and ESM-1. Associations independent of insulin resistance and classic adipokines. Suggests compensatory upregulation during early metabolic stress. IMPLICATION: FAM132A as early biomarker for pediatric vascular injury.
Identifiers
42337032What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.